Last reviewed · How we verify
AZTherapies, Inc. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| ALZT-OP1b | ALZT-OP1b | phase 3 | Small molecule disease-modifying agent | Neurology | ||
| ALZT-OP1a | ALZT-OP1a | phase 3 | Multi-target small molecule | Neurology |
Therapeutic area mix
- Neurology · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for AZTherapies, Inc.:
- AZTherapies, Inc. pipeline updates — RSS
- AZTherapies, Inc. pipeline updates — Atom
- AZTherapies, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). AZTherapies, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/aztherapies-inc. Accessed 2026-05-16.